Literature DB >> 31636908

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.

Juanjuan Zhao1, Yongping Song1, Delong Liu1,2.   

Abstract

[This corrects the article DOI: 10.1186/s40364-019-0170-2.].
© The Author(s). 2019.

Entities:  

Year:  2019        PMID： 31636908      PMCID： PMC6796449          DOI： 10.1186/s40364-019-0172-0

Source DB:  PubMed          Journal:  Biomark Res        ISSN： 2050-7771


Correction to: Biomark Res (2019) 7:19 https://doi.org/10.1186/s40364-019-0170-2 The original article [1] contains an error in the legend of Fig. 1 whereby it is incorrectly stated that MEC stands for ‘mitoxantrone, etoposide, cyclophosphamide’. It should instead be stated that MEC stands for ‘mitoxantrone, etoposide, cytarabine’.
  1 in total

Review 1.  Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.

Authors:  Juanjuan Zhao; Yongping Song; Delong Liu
Journal:  Biomark Res       Date:  2019-09-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.